2022;1(1):EVIDoa2100009.This study demonstrates an elegant approach to interleukin-based strategies in IHD as low-dose IL-2 causes dose dependent Treg differentiation and promotes resolution of inflammation without affecting the immune systems host-defence. This evidence concerns the gene IL2 and myocardial ischemia.